The JCPG prioritizes accessibility to these critical models in the otherwise resource-limited rare disease therapeutic research field. In collaboration with the Rare Disease Translational Center’s preclinical pipeline, the models incorporated into the program are used to test therapeutics, promoting their ultimate translation to the clinic.
The JCPG works to develop and characterize new mouse models of rare disease to advance therapeutic research. Partners can engage with the JCPG at any stage of the model development and therapeutic testing process. The JCPG is an accessible and scalable pipeline that integrates capabilities and services to support a broad array of partners including rare disease families, clinicians, researchers, and therapeutic developers. It’s never too soon to start a conversation with our team!
Developing precision treatments for rare disease requires a holistic approach that combines mouse model expertise with clinical and scientific partners with passion to advance cures. The JCPG gathers and evaluates nominations from the rare disease community and offers a streamlined process to:
The JAX Center for Precision Genetics (JCPG) brings together a multi-disciplinary team of over 20 members of the JAX faculty and research staff — including geneticists and genetics technology experts, quantitative and computational biologists, clinical experts in specific disease areas, patient organizations, and world leaders in the development of precision animal models of disease.
The JCPG (U54 OD030187) is led by Cathleen Lutz, Ph.D. and Stephen Murray. Ph.D. and is funded by the NIH Office of Research Infrastructure Programs through the Office of the Director. Efforts at JAX are complemented by funded centers at Baylor College of Medicine and University of Alabama Birmingham.
New five-year NIH grant totaling $10.6M funds JAX center to fast-track treatment-focused research for rare genetic disorders.
Chris Brannigan has recently completed a 700 mile trek barefoot across England to raise awareness for the rare disease affecting his daughter Hasti: Cornelia de Lange syndrome (CdLS). The march took 35 days, but it is only the start of the Brannigan’s rare disease odyssey.
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.